Please help explain this figure Fig. 5: LAPTM5 transports HIV-1 Env to thelysosome for degradation.ab120,100-* 80-x43 x 137 x 146NL4-3 Vpr-Bal Vpr-60-응 40어MockMockMockMock150-4007 x7020-50-gp120E 300-Tx98x 66120,100-* 80-60-40-20-gp4150-200-37-Pr55-Gag100-37-LAPTM50.51.0GAPDH0.5Mock1.0 Vector (pg)Bal Vpr-LAPTM5No Treat. BFLA CLQLAPTM5MockLAPTM5MockLAPTM5MockNL4-3 Bal AD8Bal Vpr-150-MockMockVpr-gp12050-LysosomelysatesCell lysatesPr55-Gag37-BFLANo Treat.BFLALAPTM5e37-LAPTM5-GFPGAPDHLAPTM5150-EnvMockМоcкGagDAPILAPTM5MergeMockgp12050-37-Pr55-GagLAPTM5GFPLAMP137-EnvGagGAPDHDAPIBal Vpr-Mergep24 (%)LAPTM5МockLAPTM5LAPTM5LAPTM5No Treat.LAPTM5BFLALAPTM5BFLA No Treat. *LAPTM5gp120 (ng/mL)No Treat. LAPTM5МockBFLA LAPTM5CLQ\No Treat.LAPTM5MockLAPTM5

"ANSWER By causing damage to HIV-1 Env, LAPTM5 transports it to the lysosome. With Vpr-defective…

Fig. 5: LAPTM5 transports HIV-1 Env to the lysosome for degradation. a 120, x43 x 137 x146 NL4-3 Vpr- 100- 80- 60- 8 40- 20- Bal Vpr- d Mock gp120 150- Mock 400, x70 x 98 х66 50- 300- T gp41 200- 120, 100- * 80- 60- 40- 50- Pr55-Gag 37- 100- LAPTM5 37- Mock LAPTM5 0.5 GAPDH 1.0 C 0.5 1.0 Vector (ug) 20- Bal Vpr- No Treat. BFLA Treat LAPTMS CLQ LAPTM5 NL4-3 Bal AD8 LAPTM5 Bal Vpr- 150- Mock Vpr- gp120 50- Lysosome lysates Cell lysates Pr55-Gag 37- No Treat. BFLA LAPTM5 e 37- - \No Treat. BFLA GAPDH LAPTM5 Mock LAPTM5-GFP Mock Mock Env Gag DAPI 150- Merge gp120 50- Pr55-Gag LAPTM5 LAMP1 GFP 37- Env GAPDH Gag Bal Vpr- DAPI Merge gp120 (%) p24 (%) Mock LAPTM5 Mock LAPTM5 Mock Mock LAPTM5 No Treat. BFLA LAPTM5 LAPTM5 Mock LAPTM5 Mock LAPTM5 BFLA_ No Treat. * gp120 (ng/mL) BFLA LAPTM5 CLQ LAPTM5 LAPTM5

Fig. 5: LAPTM5 transports HIV-1 Env to the lysosome for degradation. a 120, x43 x 137 x146 NL4-3 Vpr- 100- 80- 60- 8 40- 20- Bal Vpr- d Mock gp120 150- Mock 400, x70 x 98 х66 50- 300- T gp41 200- 120, 100- * 80- 60- 40- 50- Pr55-Gag 37- 100- LAPTM5 37- Mock LAPTM5 0.5 GAPDH 1.0 C 0.5 1.0 Vector (ug) 20- Bal Vpr- No Treat. BFLA Treat LAPTMS CLQ LAPTM5 NL4-3 Bal AD8 LAPTM5 Bal Vpr- 150- Mock Vpr- gp120 50- Lysosome lysates Cell lysates Pr55-Gag 37- No Treat. BFLA LAPTM5 e 37- - \No Treat. BFLA GAPDH LAPTM5 Mock LAPTM5-GFP Mock Mock Env Gag DAPI 150- Merge gp120 50- Pr55-Gag LAPTM5 LAMP1 GFP 37- Env GAPDH Gag Bal Vpr- DAPI Merge gp120 (%) p24 (%) Mock LAPTM5 Mock LAPTM5 Mock Mock LAPTM5 No Treat. BFLA LAPTM5 LAPTM5 Mock LAPTM5 Mock LAPTM5 BFLA_ No Treat. * gp120 (ng/mL) BFLA LAPTM5 CLQ LAPTM5 LAPTM5

Human Physiology: From Cells to Systems (MindTap Course List)

9th Edition

ISBN:9781285866932

Author:Lauralee Sherwood

Publisher:Lauralee Sherwood

Chapter12: Body Defenses

Section: Chapter Questions

Problem 2TAHL

See similar textbooks

Similar questions

Which of the following is the most likely explanation for an individual who lacks CCR5 as a result of a homozygous defect in the CCR5 gene becoming infected with HIV? a. The mutated CCR5 genes reverted to the normal form, rendering macrophages susceptible to macrophagetropic HIV variants. b. The macrophage-tropic HIV variant entered host cells using CD4 alone. c. The viral nucleic acid alone was taken up by cells, as in cell transformation by bacterial DNA. d. The individual had received a transplant of HIV-infected cells expressing normal CCR5. e. The primary infection involved a lymphocyte-tropic strain of HIV that used CXCR4 as its co-receptor.
Explain : Vpr counteracts LAPTM5 to promote HIV-1 infection in macrophages
Prior to entry, the _________ glycoprotein of the HIV virus recognizes the ______ receptor on the surface of the macrophage. a. CCR5; gp120 b. CXCR4; CCR5 c. CD4; CCR5 d. gp120; CD4
Please help explain this LAPTM5 Transport HIV-1 Env to the lysosome for degradation
Let’s say there are two closely related viruses, let’s call them Guernsey virus and Micro virus. These two viruses only infect epithelial cells. Their surface antigens are sufficiently similar that there are a number of shared epitopes between the two viruses. Choose one of the following: A) If you get infected and successfully recover from one virus, it’s quite possible that you’ll have neutralizing antibodies against the other. B) If you get infected and successfully recover from one virus, you’ll still be susceptible to the other one because the antigens aren’t exactly the same. C) If you get infected and successfully recover from one virus, it’s likely that getting infected with the other virus will be worse because of the common phenomena of antibody-dependent enhancement. D) Not enough information has been given.
Efforts to produce an HIV vaccine have met with limited success. What aspects of the virus and its replicative strategy make it difficult to produce a vaccine against HIV? What other kind of virus might be similarly different to vaccinate against? What similarities and differences exist between the two types of virus that account for the differences in vaccine production?
We now have at least three SARS-CoV-2/COVID-19 vaccines approved by the FDA for use in the United States. These vaccines cause cells in the body to make the spike protein that is on the surface of the virus, and subsequently, stimulate an antibody response to this antigen. A. What do these antibodies do to prevent infection by SARS-CoV-2? How do they interact with the virus particles? B. Which kind of cells in the immune system are responsible for synthesizing these antibodies?
Which best describe the HIV REV protein? Code for proteins necessary for synthesis of the viral capsids. Code for proteins that is cleaved to produce reserve transcriptase. Binds a specific stem-loop structure in the viral RNAs into cytosol. None of the above.
please help explain HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells
How is the gp120 protein important to HIV and its ability to confound the immune system?
Antigenic drift refers to: A.The reassortment of genomic segments from different viruses B.Cytotoxic T cells identifying viral infected host cells C.The accumulation of mutations in the viral genome due to an error prone polymerase D.Antigen presenting cells failure to recognize the influenza virus
People with the CCR5Δ32 mutation of a T-cell surface protein can be exposed to some strains of HIV-1 without becoming sick. What step of the virus life cycle is likely to be inhibited with this mutation? a. Release b. Reverse transcription c. Uncoating d. Attachment